Shape-changing IOL for presbyopia offers long-term stable vision

Article

The Grail study finds the device can offer positive outcomes for patients.

The Juvene modular, shape-changing, fluid optic IOL from LensGen Inc. Image courtesy of LensGen Inc.

The Juvene modular, shape-changing, fluid optic IOL from LensGen Inc. Image courtesy of LensGen Inc.

Reviewed by Sumit Garg, MD

The Juvene IOL (LensGen, Inc) for presbyopia provided good outcomes to patients with a full range of visual acuity (VA) from distance to near for up to 24 months after implantation in the Grail study.

The Juvene IOL is a fluid-filled curvature-changing lens that has 2 components: a base lens with capsule-filling, circumferential haptics and a shape-changing fluid optic that fits into the base lens and provides incremental refractive power for a full, continuous range of vision, according to Sumit Garg, MD, vice chair of clinical ophthalmology, medical director and a professor in Cataract, Refractive, External Disease and Corneal Surgery at the Gavin Herbert Eye Institute at University of California, Irvine.

In this trial, the investigators measured the manifest refractions, best-corrected distance visual acuity, distance-corrected intermediate vision (DCIVA) at 66 cm, the distance-corrected near vision (DCNVA) at 40 cm VAs, and distance-corrected defocus curves using the M&S Technologies Clinical Trial Suite in photopic lighting. A total of 58 eyes of 42 patients were implanted with the IOL in the Grail study; 27 patients completed the 2-year evaluation. Many did not undergo evaluations because of the pandemic.

The mean monocular DCVA was 20/20, the DCIVA was 20/25, and the DCNVA was 20/40. The binocular VAs improved across all distances for all patients, Garg explained.

“It was notable that the broad monocular defocus curve showed 3.5 D of usable vision above 20/40, which was comparable to that achieved with the high-quality Vivity IOL [Alcon]. Binocular summation showed 4.5 D of usable vision at 20/40 or better,” he said.

Importantly, results demonstrated the long-term stability of the vision. “From 12 months to 24 months, there was no change seen in the effect of the IOL,” he said. Additionally, contrast vision was similar to that of a TECNIS Monofocal IOL with very high patient satisfaction of visual quality and range. 

“Implantation of the Juvene IOL provided good outcomes across the full visual range out to 2 years in the Grail study,” Garg said. “The visual improvements remained stable over time.”

Sumit Garg, MD

E: gargs@hs.uci.edu

This article was adapted from Garg’s presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting in Washington, DC. He is a member of the medical advisory board to LensGen, Inc.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.